Abstract
Previous studies have shown that microRNA (miR)-610 is crucial in a variety of biological processes in various types of human cancer cells. However, the role of this microRNA in glioblastoma (GBM) is presently unclear. In this study, the role of miR‑610 in cell proliferation was investigated in GBM. It was demonstrated that miR‑610 expression is markedly downregulated in GBM cells and GBM tissues compared with normal human astrocytes (NHAs) and normal brain tissue, respectively. Ectopic expression of miR‑610 reduced the proliferation and anchorage‑independent growth of GBM cells, whereas inhibition of miR‑610 promoted this effect. Bioinformatics analysis further revealed cyclin D2 (CCND2) and AKT3, putative tumor promoters, as potential targets of miR‑610. Data from reporter assays showed that miR‑610 directly binds to the 3'‑untranslated region of CCND2 and AKT3 mRNA, and represses their expression at the transcriptional and translational levels. In conclusion, the data provide compelling evidence that miR‑610 functions as an anti‑onco‑miRNA, which is important in inhibiting cell proliferation in GBM, and its anti‑oncogenic effects are mediated chiefly through direct suppression of CCND2 and AKT3 expression.
References
Aug 27, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Y TeradaF Marumo
Oct 29, 2002·Diabetes·Denis FéliersDaniel J Riley
Jan 28, 2004·Cell·David P Bartel
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Aug 16, 2005·Current Opinion in Genetics & Development·Eric A Miska
Oct 19, 2006·Oncology·Young Hwa SoungSug Hyung Lee
Dec 21, 2006·Cancer Research·Briony E CristianoRichard B Pearson
Aug 1, 2008·Nature·Daehyun BaekDavid P Bartel
Aug 2, 2008·The New England Journal of Medicine·Patrick Y Wen, Santosh Kesari
Mar 25, 2010·BMC Cancer·Ulrich LehmannFlorian Länger
Jul 21, 2010·Journal of Molecular Signaling·Sanjit K RoySharmila Shankar
Dec 23, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jing WangLei Wei
Feb 7, 2012·Molecular Medicine Reports·Songchao LiXiaokun Zhao
Sep 12, 2012·Oncogene·R Koyama-NasuT Akiyama
Nov 20, 2012·Neurosurgery·Phillip V Parry, Johnathan A Engh
Apr 23, 2013·Cellular Signalling·Ekta AgarwalSanjib Chowdhury
Jun 29, 2013·Journal of Experimental & Clinical Cancer Research : CR·Yong GuoFenghua Chen
Oct 30, 2013·Oncogene·A FormosaE Candi
Jun 20, 2014·World Journal of Gastroenterology : WJG·Cheng-Chi ChangMin-Liang Kuo
Jun 27, 2014·BioMed Research International·Monika Paul-SamojednyJan Kowalski
Oct 7, 2014·Cell Reports·Hiroki TakaiTetsu Akiyama
Citations
Aug 28, 2018·Journal of Cellular Physiology·Gui-Ling RenXiao-Ming Meng
Aug 10, 2017·Oncology Reports·Jing SuiGe-Yu Liang
Jan 31, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ruizhe WangWen Yuan
Sep 17, 2017·Oncotarget·Chi JinZhonglin Shan
Dec 13, 2017·Oncotarget·Guangjing ZhangShijun Feng
Aug 26, 2018·BMC Cancer·Erika DurinikovaMiroslava Matuskova
Sep 19, 2019·Cell Death & Disease·Pinakin PandyaNoah Isakov
Aug 28, 2020·Cancer Management and Research·Jian Pei Zhao, Li Li Chen
Jan 3, 2020·Biotechnology Letters·Yujin LiGaopeng Xiao
Apr 18, 2018·BioMed Research International·Juan ChenTingting Xiao
Sep 25, 2020·Journal of Biochemistry·Fang LiuZhao-Dong Huang
Dec 29, 2020·Seminars in Cancer Biology·Md Sahab UddinGhulam Md Ashraf
Mar 17, 2021·Experimental Cell Research·Lei ChengYiwei Liao
Aug 20, 2021·International Journal of Nanomedicine·Ting LiuLu Zhang
Oct 4, 2020·Experimental and Molecular Pathology·Omidvar RezaeiSoudeh Ghafouri-Fard
Jun 6, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Qian-Yu LiHongmian Zhao
Jul 20, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wenjie HuZheng Sui